Connect your AI

ADMA Biologics ADMA Expected sale proceeds

Expected sale proceeds at other companies

NovavaxNVAX

$39.75M—

RB GlobalRBA

$2.4M+118%

WingstopWING

$0-100%

Healthcare Realty TrustHR

$29.32M+51.5%

RLJ Lodging TrustRLJ

$17.26M+254%

JetBlue AirwaysJBLU

$40M-9.1%

Other financials

Income statement

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

Market cap$2.02B-54.5%

Profitability

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyHeldForSale.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's expected sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ADMA Biologics's expected sale proceeds?: ADMA Biologics (ADMA) reported expected sale proceeds of $5M in Q1 2026.